(2e,2'e)-N,N'-(pyridine-2,6-diyl)bis(3-(furan-2-yl)acrylamide)

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (2e,2'e)-N,N'-(pyridine-2,6-diyl)bis(3-(furan-2-yl)acrylamide)
• 英文别名: (E)-3-(furan-2-yl)-N-[6-[[(E)-3-(furan-2-yl)prop-2-enoyl]amino]pyridin-2-yl]prop-2-enamide
• 化学式: C₁₉H₁₅N₃O₄
• 分子量: 349.3
• InChiKey: YUFJMFXVUUMVCA-GFULKKFKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.4
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Use of aromatic ring drug in inhibiting key transcription factor of malignant melanoma
  申请人：SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES

  公开号：US11077097B2

  公开（公告）日：2021-08-03

  Provided is the use of an aromatic ring drug in inhibiting a key transcription factor of malignant melanoma. In particular, provided is the use of a compound as represented by formula A, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition or preparation. The pharmaceutical composition or preparation is used for: (a) inhibiting a key transcriptional regulatory factor of malignant melanoma, namely MITF (Microphthalmia-associated Transcription Factor); (b) treating MITF-related diseases such as melanoma, pancreatic cancer, skin hypersensitivity and asthma; and (c) regulating physiological activities in which MITF is involved, such as skin whitening. In the formula, each group is as defined in the description.

  本发明提供了芳香环药物在抑制恶性黑色素瘤关键转录因子中的用途。特别是，提供了式 A 所代表的化合物或其光学异构体或其外消旋物或其溶液或其药学上可接受的盐在制备药物组合物或制剂中的用途。该药物组合物或制剂用于(a) 抑制恶性黑色素瘤的关键转录调控因子，即 MITF（微眼相关转录因子）；(b) 治疗与 MITF 相关的疾病，如黑色素瘤、胰腺癌、皮肤过敏和哮喘；以及 (c) 调节 MITF 参与的生理活动，如皮肤美白。在配方中，各组的定义见说明。
• USE OF AROMATIC RING DRUG IN INHIBITING KEY TRANSCRIPTION FACTOR OF MALIGNANT MELANOMA
  申请人：SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES

  公开号：US20200129490A1

  公开（公告）日：2020-04-30

  Provided is the use of an aromatic ring drug in inhibiting a key transcription factor of malignant melanoma. In particular, provided is the use of a compound as represented by formula A, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition or preparation. The pharmaceutical composition or preparation is used for: (a) inhibiting a key transcriptional regulatory factor of malignant melanoma, namely MITF (Microphthalmia-associated Transcription Factor); (b) treating MITF-related diseases such as melanoma, pancreatic cancer, skin hypersensitivity and asthma; and (c) regulating physiological activities in which MITF is involved, such as skin whitening. In the formula, each group is as defined in the description.